DOCSLIB.ORG

Annual Activity Report 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Activity Report 2018 Annex 1 to the Decision of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking no. IMI2-GB-DEC-2019-11 approved on 21.06.2019 1 Contents Factsheet – IMI at a glance ..................................................................................................................... 4 Foreword.................................................................................................................................................. 6 Executive summary ................................................................................................................................. 8 1 Implementation of the Annual Work Plan 2018 .............................................................................. 13 1.1 Key objectives in 2018 ........................................................................................................... 13 1.2 Research & innovation activities............................................................................................ 15 IMI projects are delivering results in disease areas with high unmet medical and social needs 16 IMI projects have an impact on the regulatory framework ................................................ 19 IMI projects are delivering tools and resources that are accessible to the wider scientific community ...................................................................................................................................... 20 Collaboration among consortia and with external bodies and other sectors ..................... 22 1.3 Stakeholder engagement ...................................................................................................... 23 SME involvement ............................................................................................................... 23 Patient involvement ........................................................................................................... 23 Interactions and involvement with regulatory authorities .................................................. 24 1.4 Calls for proposals and grant information .............................................................................. 25 Launch and management of Calls in 2018 ........................................................................ 25 Interim reviews for IMI projects .......................................................................................... 44 Progress against key performance indicators (KPIs) and statistics .................................. 48 1.5 Dissemination and information about project results ............................................................ 50 1.6 Operational budget execution................................................................................................ 55 1.7 EFPIA and IMI2 Associated Partner contributions ................................................................ 60 2 Support to operations ..................................................................................................................... 71 2.1 Communication activities ....................................................................................................... 72 2.2 Legal and financial framework ............................................................................................... 79 2.3 Budgetary and financial management ................................................................................... 80 2018 budget approval ........................................................................................................ 80 Budget transfers ................................................................................................................ 82 Budget execution ............................................................................................................... 83 Overview of the carry over appropriations to 2019 ............................................................ 85 2.4 Procurement and contracts ................................................................................................... 86 2.5 IT and logistics ....................................................................................................................... 87 2.6 Human resources .................................................................................................................. 89 2.7 Data protection ...................................................................................................................... 91 2.8 Access to documents ............................................................................................................ 91 3 Governance .................................................................................................................................... 92 3.1 Governing Board ................................................................................................................... 92 2 3.2 Executive Director ................................................................................................................. 92 3.3 States Representatives Group .............................................................................................. 92 3.4 Scientific Committee .............................................................................................................. 93 3.5 Stakeholder Forum ................................................................................................................ 93 3.6 Strategic Governing Groups (SGGs) ..................................................................................... 93 3.7 Associated Partners .............................................................................................................. 94 4 Internal control framework .............................................................................................................. 96 4.1 Financial procedures ............................................................................................................. 96 4.2 Ex ante controls on operational expenditure ......................................................................... 96 4.3 Ex-post control of operational expenditure and error rates identified.................................. 105 4.4 Audit of the European Court of Auditors .............................................................................. 110 4.5 Internal audit ........................................................................................................................ 112 4.6 Risk management and conflict of interest ........................................................................... 113 4.7 Fraud prevention and detection ........................................................................................... 115 4.8 Compliance and effectiveness of internal control ................................................................ 116 5 Management assurance ............................................................................................................... 118 5.1 Elements supporting assurance .......................................................................................... 118 5.2 Reservations ........................................................................................................................ 119 5.3 Overall conclusion ............................................................................................................... 119 6 Statement of the manager in charge of risk management and internal control ........................... 120 7 Declaration of assurance ............................................................................................................. 121 Annexes ............................................................................................................................................... 122 Annex 1 - Organisational chart ........................................................................................................ 123 Annex 2 - Establishment plan .......................................................................................................... 124 Annex 3 – Project outputs ................................................................................................................ 127 IMI1 project outputs ...................................................................................................................... 128 IMI2 project outputs ...................................................................................................................... 145 Annex 4 - Publications from projects ............................................................................................... 154 Annex 5 - Patents from IMI2 projects .............................................................................................. 161 Annex 6 - Scoreboard of Horizon 2020 common KPIs .................................................................... 162 Annex 7 - Indicators for monitoring cross-cutting issues ................................................................. 167 Annex 8 - Scoreboard of KPIs specific to IMI .................................................................................. 177 Annex 9 – Final annual accounts ..................................................................................................... 182 Annex 10 - Materiality criteria .......................................................................................................... 184 Annex 11 – Media highlights ...........................................................................................................
Load more

Recommended publications
  • Guide to Publication Policies of the Nature Journals
    GUIDE TO PUBLICATION POLICIES OF THE NATURE JOURNALS Last updated on 30 April 2009. Editorial Policies NATURE JOURNALS' POLICIES ON PUBLICATION ETHICS Nature journals' authorship policy Being an author The Nature journals do not require all authors of a research paper to sign the letter of submission, nor do they impose an order on the list of authors. Submission to a Nature journal is taken by the journal to mean that all the listed authors have agreed all of the contents. The corresponding (submitting) author is responsible for having ensured that this agreement has been reached, and for managing all communication between the journal and all co-authors, before and after publication. Any changes to the author list after submission, such as a change in the order of the authors, or the deletion or addition of authors, needs to be approved by a signed letter from every author. Responsibilities of senior team members on multi-group collaborations The editors at the Nature journals assume that at least one member of each collaboration, usually the most senior member of each submitting group or team, has accepted responsibility for the contributions to the manuscript from that team. This responsibility includes, but is not limited to: (1) ensuring that original data upon which the submission is based is preserved and retrievable for reanalysis; (2) approving data presentation as representative of the original data; and (3) foreseeing and minimizing obstacles to the sharing of data, materials, algorithms or reagents described in the work. Author contributions statementsAuthors are required to include a statement of responsibility in the manuscript that specifies the contribution of every author.
    [Show full text]
  • The Nature Index Journals
    The Nature Index journals The current 12-month window on natureindex.com includes data from 57,681 primary research articles from the following science journals: Advanced Materials (1028 articles) American Journal of Human Genetics (173 articles) Analytical Chemistry (1633 articles) Angewandte Chemie International Edition (2709 articles) Applied Physics Letters (3609 articles) Astronomy & Astrophysics (1780 articles) Cancer Cell (109 articles) Cell (380 articles) Cell Host & Microbe (95 articles) Cell Metabolism (137 articles) Cell Stem Cell (100 articles) Chemical Communications (4389 articles) Chemical Science (995 articles) Current Biology (440 articles) Developmental Cell (204 articles) Earth and Planetary Science Letters (608 articles) Ecology (259 articles) Ecology Letters (120 articles) European Physical Journal C (588 articles) Genes & Development (193 articles) Genome Research (184 articles) Geology (270 articles) Immunity (159 articles) Inorganic Chemistry (1345 articles) Journal of Biological Chemistry (2639 articles) Journal of Cell Biology (229 articles) Journal of Clinical Investigation (298 articles) Journal of Geophysical Research: Atmospheres (829 articles) Journal of Geophysical Research: Oceans (493 articles) Journal of Geophysical Research: Solid Earth (520 articles) Journal of High Energy Physics (2142 articles) Journal of Neuroscience (1337 articles) Journal of the American Chemical Society (2384 articles) Molecular Cell (302 articles) Monthly Notices of the Royal Astronomical Society (2946 articles) Nano Letters
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Cancer-Milestones December 2020
    www.nature.com/collections/cancer-milestones December 2020 Cancer Produced by: With support from: Nature Genetics and Nature Medicine Cancer MILESTONES S2 Foreword S3 Timeline S4 Routes to resistance S5 Tracking cancer in liquid biopsies S6 When cancer prevention went viral S7 A licence to kill S8 Sitting on the fence S9 Not a simple switch S10 Sequencing the secrets of the cancer genome S11 Unleashing the immune system against cancer S12 Engineering armed T cells for the fight S13 Oncohistones: epigenetic drivers of cancer S14 Tumour evolution: from linear paths to branched trees S15 Undruggable? Inconceivable S16 Good bacteria make for good cancer therapy S17 The AI revolution in cancer Credit: S.Fenwick/Springer Nature Limited CITING THE MILESTONES VISIT THE SUPPLEMENT ONLINE SUBSCRIPTIONS AND CUSTOMER SERVICES Nature Milestones in Cancer includes Milestone articles written The Nature Milestones in Cancer supplement can be found at Springer Nature, Subscriptions, by our editors and an online Collection of previously published www.nature.com/collections/cancer-milestones Cromwell Place, Hampshire International Business Park, material. To cite the full project, please use Nature Milestones: Lime Tree Way, Basingstoke, Cancer https://www.nature.com/collections/cancer-milestones CONTRIBUTING JOURNALS Hampshire RG24 8YJ, UK (2020). Should you wish to cite any of the individual Milestones, BMC Cancer, Nature, Nature Cancer, Nature Communications, Tel: +44 (0) 1256 329242 please list Author, A. Title. Nature Milestones: Cancer <Article URL> Nature Genetics, Nature Medicine, Nature Reviews Cancer, [email protected] (2020). For example, Milestone 1 is Valtierra, I. Routes to resistance. Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery, Customer serviCes: www.nature.com/help Nature Milestones: Cancer https://www.nature.com/articles/ Nature Reviews Gastroenterology & Hepatology, d42859-020-00069-6 (2020).
    [Show full text]
  • Understanding Biological Design from Synthetic Circuits
    REVIEWS MODELLING Synthetic biology: understanding biological design from synthetic circuits Shankar Mukherji* and Alexander van Oudenaarden‡ Abstract | An important aim of synthetic biology is to uncover the design principles of natural biological systems through the rational design of gene and protein circuits. Here, we highlight how the process of engineering biological systems — from synthetic promoters to the control of cell–cell interactions — has contributed to our understanding of how endogenous systems are put together and function. Synthetic biological devices allow us to grasp intuitively the ranges of behaviour generated by simple biological circuits, such as linear cascades and interlocking feedback loops, as well as to exert control over natural processes, such as gene expression and population dynamics. 10–12 Modularity One of the most astounding findings of the Human potential clinical applications . In this Review, however, A property of a system such Genome Project was that our genome contains as many we focus on how synthetic circuits help us to under- that it can be broken down into genes as that of Drosophila melanogaster. This finding stand how natural biological systems are genetically discrete subparts that perform begged the question: how do you get one organism to assembled and how they operate in organisms from specific tasks independently of look like a fly and another like a human with the same microbes to mammalian cells. In this light, synthetic the other subparts. number of genes? One possibility is that the rich rep- circuits have been crucial as simplified test beds in Bioremediation ertoire of non-protein-coding sequences found in the which to refine our ideas of how similarly structured The treatment of pollution with genomes of complex organisms adds many new parts natural networks function, and they have served as microorganisms.
    [Show full text]
  • List Stranica 1 Od
    list product_i ISSN Primary Scheduled Vol Single Issues Title Format ISSN print Imprint Vols Qty Open Access Option Comment d electronic Language Nos per volume Available in electronic format 3 Biotech E OA C 13205 2190-5738 Springer English 1 7 3 Fully Open Access only. Open Access. Available in electronic format 3D Printing in Medicine E OA C 41205 2365-6271 Springer English 1 3 1 Fully Open Access only. Open Access. 3D Display Research Center, Available in electronic format 3D Research E C 13319 2092-6731 English 1 8 4 Hybrid (Open Choice) co-published only. with Springer New Start, content expected in 3D-Printed Materials and Systems E OA C 40861 2363-8389 Springer English 1 2 1 Fully Open Access 2016. Available in electronic format only. Open Access. 4OR PE OF 10288 1619-4500 1614-2411 Springer English 1 15 4 Hybrid (Open Choice) Available in electronic format The AAPS Journal E OF S 12248 1550-7416 Springer English 1 19 6 Hybrid (Open Choice) only. Available in electronic format AAPS Open E OA S C 41120 2364-9534 Springer English 1 3 1 Fully Open Access only. Open Access. Available in electronic format AAPS PharmSciTech E OF S 12249 1530-9932 Springer English 1 18 8 Hybrid (Open Choice) only. Abdominal Radiology PE OF S 261 2366-004X 2366-0058 Springer English 1 42 12 Hybrid (Open Choice) Abhandlungen aus dem Mathematischen Seminar der PE OF S 12188 0025-5858 1865-8784 Springer English 1 87 2 Universität Hamburg Academic Psychiatry PE OF S 40596 1042-9670 1545-7230 Springer English 1 41 6 Hybrid (Open Choice) Academic Questions PE OF 12129 0895-4852 1936-4709 Springer English 1 30 4 Hybrid (Open Choice) Accreditation and Quality PE OF S 769 0949-1775 1432-0517 Springer English 1 22 6 Hybrid (Open Choice) Assurance MAIK Acoustical Physics PE 11441 1063-7710 1562-6865 English 1 63 6 Russian Library of Science.
    [Show full text]
  • Curriculum Vitae – WENJUN ZHANG
    Curriculum Vitae – WENJUN ZHANG Department of Chemical and Biomolecular Engineering, University of California, Berkeley 201 Gilman Hall, Berkeley, CA 94720 http://www.cchem.berkeley.edu/wzgrp Tel: (510)643-8682, [email protected] https://scholar.google.com/citations?hl=en&user=NUYglIoAAAAJ&view_op=list_works&sortby=pubdate PROFESSIONAL EXPERIENCE Co-director, Agilent/UC Berkeley Synthetic Biology Institute (SBI) 2019 to current Associate Professor, Dept. of Chemical and Biomolecular Engineering, UC Berkeley 2018 to current Biologist Faculty Sci/Engr, Lawrence Berkeley National Laboratory 2014 to current Assistant Professor, Dept. of Chemical and Biomolecular Engineering, UC Berkeley 2011-2018 EDUCATION Research Fellow, Harvard Medical School (adviser: Christopher T. Walsh) 2009-2011 Ph.D., Chemical Engineering, University of California, Los Angeles (adviser: Yi Tang) 2004-2009 M.S., Biochemistry and Molecular Biology, Nanjing University, China (adviser: Genxi Li) 2002-2004 B.S., Biochemistry, DII, Nanjing University, China 1998-2002 AWARDS AND HONORS Presidential Early Career Award for Scientists and Engineers (PECASE) (2019) Scialog Fellow, Research Corporation and the Gordon and Betty Moore Foundation (2018) American Cancer Society Research Scholar (2017) Chau Hoi Shuen Foundation Women in Science Program New Research Grant Award (2017) Chan Zuckerberg Biohub Investigator (2017) Alfred P . Sloan Research Fellow (2016) Paul Saltman Memorial Award in Bioinorganic Chemistry (2016) NIH Director's New Innovator Award (2015) Hellman Fellow (2015) F1000Prime Faculty (Chemical Biology, Small Molecule Chemistry section) (2015) The Charles R. Wilke Endowed Chair in Chemical Engineering, UC Berkeley (2014) University of California Cancer Research Coordinating Committee Research Award (2013) Pew Scholar (2012) Energy Biosciences Institute Proposal Award (2011, 2014) Outstanding Ph.D.
    [Show full text]
  • Michael Lynch
    1 Michael Lynch Center for Mechanisms of Evolution, Biodesign Institute Arizona State University Tempe, AZ 85287 Phone: 480-965-0868 Email: [email protected] Birth: 6 December 1951, Auburn, New York Undergraduate education: St. Bonaventure University, Biology - B.S., 1973. Graduate education: University of Minnesota, Ecology and Behavioral Biology - Ph.D., 1977 (advisor: J. Shapiro). Areas of Interest and Research: The integration of molecular and cellular biology, genetics, and evolution; population and quantitative genetics; molecular, genomic, and phenotypic evolution. Select Professional Activities and Service: Director, Biodesign Center for Mechanisms of Evolution, Arizona State University, 2017 – present. Professor, School of Life Sciences, Arizona State University, 2017 – present. Class of 1954 Professor, 2011 – 2017. Distinguished Professor, Indiana University, 2005 – 2017. Professor; Biology, Indiana University, 2001 – 2004. Adjunct Professor, Computer Science, Indiana University, 2014 – 2017. Adjunct Professor, Physics, Indiana University, 2015 – 2017. Professor; Biology, University of Oregon, 1989 – 2001. Director, Ecology and Evolution Program, Univ. of Oregon, 1989 – 1993, 1996 – 2000. Asst., Assoc., Full Professor; Ecology, Ethology, and Evolution; University of Illinois, 1977 – 1989. Co-director, NSF IGERT Training Grant in Evolution, Development, and Genomics, 1999 – 2004. Director, NSF Genetic Mechanisms of Evolution Training Grant, 1990 – 2000. President, Genetics Society of America, 2013. President, Society for Molecular Biology and Evolution, 2009. President, American Genetic Association, 2007. President, Society for the Study of Evolution, 2000. Chair-elect, Section on Biological Sciences American Association for the Advancement of Science, 2017-2020. Vice-president, Genetics Society of America, 2012. Vice-president, Society for the Study of Evolution, 1994. Council Member, Society for the Study of Evolution, 1991 – 1993.
    [Show full text]
  • Towards Population-Scale Long-Read Sequencing
    REVIEWS Towards population-scale long-read sequencing Wouter De Coster 1,2,5, Matthias H. Weissensteiner3,5 and Fritz J. Sedlazeck 4 ✉ Abstract | Long-read sequencing technologies have now reached a level of accuracy and yield that allows their application to variant detection at a scale of tens to thousands of samples. Concomitant with the development of new computational tools, the first population-scale studies involving long-read sequencing have emerged over the past 2 years and, given the continuous advancement of the field, many more are likely to follow. In this Review, we survey recent developments in population-scale long-read sequencing, highlight potential challenges of a scaled-up approach and provide guidance regarding experimental design. We provide an overview of current long-read sequencing platforms, variant calling methodologies and approaches for de novo assemblies and reference-based mapping approaches. Furthermore, we summarize strategies for variant validation, genotyping and predicting functional impact and emphasize challenges remaining in achieving long-read sequencing at a population scale. Genome-wide association Sequencing the DNA or mRNA of multiple individuals These studies highlighted that a substantial proportion studies of one or more species (that is, population-scale sequenc- of hidden variation can be discovered with long-read (GWAS). Studies involving a ing) aims to identify genetic variation at a population sequencing. Indeed, recent long-read sequencing stud- statistical approach in genetics level to address questions in the fields of evolutionary, ies of Icelandic and Chinese populations have already to identify variants that correlate with a certain agricultural and medical research. Previous popula- identified previously undetected variants associated with 11,12 phenotype (for example, a tion studies, including genome-wide association studies height, cholesterol level and anaemia .
    [Show full text]
  • Jonathan Butcher, Polyphor, Switzerland
    1 BIO 2016 Global Workshop for Novel Anti-Infectives by Jonathan J. Butcher PhD, Polyphor Ltd, Hegenheimermattweg 125, CH-4123, Allschwil, Switzerland Discovery and Development of Novel Macrocycle Antibiotics BIO 2016 Global Workshop for Novel Anti-Infectives – June 6, 2016 2 Murepavadin (POL7080) A once in a generation discovery POL7080, antibiotic against Pseudomonas with a new mode of action POL0067 POL6137 POL7001 POL7080 CCS Protegrin I (1ZY6) Pseudomonas specific! PK/ADMET optimization Srinivas, S., et al. (2010) Science, 327: 1010 – 1012 Very potent and narrow MIC distribution Efficacy of POL7080 in a murine pneumonia (400 recent Pseudomonas strains) model against Pseudomonas aeruginosa (clinical isolate PAX11045, MIC = 0.125 mg/mL) EUCAST Antimicrobial MIC MIC Range 7 50 90 %S / %R Murepavadin 0.12 0.25 0.06 - 1 - / - 6 300 Meropenem 0.5 16 <0.03 - >64 73 / 13 MIC50 Ciprofloxacin 0.12 16 <0.06 - >32 73 / 22 Colistin 1 1 0.25 - 2 100 / - 5 200 CFU/lung 10 4 Log 3 MIC90 100 Number of isolates Numberof 2 Number of isolates of Number MIC99 0 Vehicle 0.06 0.125 0.25 0.5 11 0.5 0.06 0.25 0.125MIC (μg/mL) MIC (µg/mL) MIC (g/ml) Start of treatment POL7080POL7080 5.5 mg/kgPOL7080 11 mg/kgPOL7080 15 mg/kg 22 mg/kg POL7080 2.75 mg/kg Very potent anti-Pseudomonas activity, rapidly bactericidal at 2-4 times the MIC, with a narrow WT distribution. Excellent in vivo efficacy and safety in broad range of systemic infection models, allowed for FIM studies BIO 2016 Global Workshop for Novel Anti-Infectives – June 6, 2016 3 Murepavadin (POL7080) New class of anti-Pseudomonal antibiotics with novel mode of action PK snapshot and summary of clinical studies ongoing or completed AUC and C increase linearly with dose, t is approx.
    [Show full text]
  • Development of a Vaccine Against
    FEMS Microbiology Reviews, fuz030, 44, 2020, 123–153 doi: 10.1093/femsre/fuz030 Advance Access Publication Date: 16 December 2019 Review Article REVIEW ARTICLE Development of a vaccine against Staphylococcus Downloaded from https://academic.oup.com/femsre/article/44/1/123/5679032 by guest on 28 September 2021 aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms Lloyd S. Miller1,2,3,4,5,*, Vance G. Fowler, Jr.6,7, Sanjay K. Shukla8,9,Warren E. Rose10,11 and Richard A. Proctor10,12 1Immunology, Janssen Research and Development, 1400 McKean Road, Spring House, PA, 19477, USA, 2Department of Dermatology, Johns Hopkins University School of Medicine, 1550 Orleans Street, Cancer Research Building 2, Suite 209, Baltimore, MD, 21231, USA, 3Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Baltimore, MD, 21287, USA, 4Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, 601 North Caroline Street , Baltimore, MD, 21287, USA, 5Department of Materials Science and Engineering, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD, 21218, USA, 6Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, 315 Trent Drive, Hanes House, Durham, NC, 27710, USA, 7Duke Clinical Research Institute, Duke University Medical Center, 40 Duke Medicine Circle, Durham, NC, 27710, USA, 8Center for Precision Medicine Research, Marshfield Clinic Research Institute, 1000 North
    [Show full text]
  • IX Updating Course of Antimicrobials and Infectious Diseases
    REVISTA ESPAÑOLA DE QQuimioterapiauimioterapia SPANISH JOURNAL OF CHEMOTHERAPY ISSN: 0214-3429 Volume 32 Supplement number 2 September 2019 Pages: 01-79 IX Updating Course of Antimicrobials and Infectious Diseases Coordination: Dr. FJ. Candel González Servicio de Microbiologia Clínica Hospital Clínico San Carlos Madrid. Spain. 18 y 19 de febrero de 2019 Auditorio San Carlos. Pabellón Docente Publicación Oficial Hospital Clínico San Carlos de la Sociedad Española de Quimioterapia REVISTA ESPAÑOLA DE Quimioterapia Revista Española de Quimioterapia tiene un carácter multidisciplinar y está dirigida a todos aquellos profesionales involucrados en la epidemiología, diagnóstico, clínica y tratamiento de las enfermedades infecciosas Fundada en 1988 por la Sociedad Española de Quimioterapia Sociedad Española de Quimioterapia Indexada en Publicidad y Suscripciones Publicación que cumple los requisitos de Science Citation Index Sociedad Española de Quimioterapia soporte válido Expanded (SCI), Dpto. de Microbiología Index Medicus (MEDLINE), Facultad de Medicina ISSN Excerpta Medica/EMBASE, Avda. Complutense, s/n 0214-3429 Índice Médico Español (IME), 28040 Madrid Índice Bibliográfico en Ciencias e-ISSN de la Salud (IBECS) 1988-9518 Atención al cliente Depósito Legal Secretaría técnica Teléfono 91 394 15 12 M-32320-2012 Dpto. de Microbiología Correo electrónico Facultad de Medicina [email protected] Maquetación Avda. Complutense, s/n Kumisai 28040 Madrid [email protected] Consulte nuestra página web Impresión Disponible en Internet: www.seq.es España www.seq.es Esta publicación se imprime en papel no ácido. This publication is printed in acid free paper. LOPD Informamos a los lectores que, según lo previsto © Copyright 2019 en el Reglamento General de Protección Sociedad Española de de Datos (RGPD) 2016/679 del Parlamento Quimioterapia Europeo, sus datos personales forman parte de la base de datos de la Sociedad Española de Reservados todos los derechos.
    [Show full text]